GSK’s Blood Cancer Treatment Fails To Meet The Trial’s Primary Objective, Sending Its Shares Down
The primary objective of a late-stage study intended to demonstrate that GSK’s blood cancer drug Blenrep was superior to an already available treatment on the market was not met, the company said on Monday. As a standalone manufacturer of prescription drugs and vaccines, oncology is a major area of focus for GSK. Following its statement,…









